Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

Blank, 2005, Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy, Cancer Immunol. Immunother., 54, 307, 10.1007/s00262-004-0593-x

Cheng, 2007, The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma, J. Neuroimmunol., 185, 75, 10.1016/j.jneuroim.2007.01.012

Cleator, 2002, The biology of neoadjuvant chemotherapy for breast cancer, Endocr. Relat. Cancer, 9, 183, 10.1677/erc.0.0090183

Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat. Med., 8, 793, 10.1038/nm0902-1039c

Dunn, 2006, Interferons, immunity and cancer immunoediting, Nat. Rev. Immunol., 6, 836, 10.1038/nri1961

Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med., 192, 1027, 10.1084/jem.192.7.1027

Gallina, 2006, Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells, J. Clin. Invest., 116, 2777, 10.1172/JCI28828

Gattinoni, 2006, Adoptive immunotherapy for cancer: building on success, Nat. Rev. Immunol., 6, 383, 10.1038/nri1842

Ghebeh, 2006, The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, 8, 190, 10.1593/neo.05733

Groh, 2002, Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, 419, 734, 10.1038/nature01112

Iwai, 2002, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc. Natl. Acad. Sci. U.S.A., 99, 12293, 10.1073/pnas.192461099

Lang, 2006, Tumor immune escape mechanisms: impact of the neuroendocrine system, Cancer Immunol. Immunother., 55, 749, 10.1007/s00262-006-0126-x

Liu, 2007, Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway, Blood, 110, 296, 10.1182/blood-2006-10-051482

Martinez-Lacaci, 2007, Tumour cells resistance in cancer therapy, Clin. Transl. Oncol., 9, 13, 10.1007/s12094-007-0004-9

Muhlbauer, 2006, PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis, J. Hepatol., 45, 520, 10.1016/j.jhep.2006.05.007

Ohigashi, 2005, Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer, Clin. Cancer Res., 11, 2947, 10.1158/1078-0432.CCR-04-1469

Parsa, 2007, Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nat. Med., 13, 84, 10.1038/nm1517

Sun, 2006, MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA, Nat. Immunol., 7, 375, 10.1038/ni1308

Thompson, 2006, Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up, Cancer Res., 66, 3381, 10.1158/0008-5472.CAN-05-4303

Venkatesan, 2006, PI 3 kinase-dependent Akt kinase and PKCepsilon independently regulate interferon-gamma-induced STAT1alpha serine phosphorylation to induce monocyte chemotactic protein-1 expression, Cell Signal, 18, 508, 10.1016/j.cellsig.2005.05.022

Wu, 2006, Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance, Acta Histochem., 108, 19, 10.1016/j.acthis.2006.01.003

Yamazaki, 2002, Expression of programmed death 1 ligands by murine T cells and APC, J. Immunol., 169, 5538, 10.4049/jimmunol.169.10.5538

Zhang, 2007, The net effect of costimulatory blockers is dependent on the subset and activation status of the autoreactive T cells, J. Immunol., 178, 474, 10.4049/jimmunol.178.1.474